Valuation: MannKind Corporation

Market Cap 1.24B 1.07B 1B 914M 1.72B 118B 1.75B 11.77B 4.6B 59.28B 4.65B 4.55B 197B P/E 2026 *
-21.1x
P/E 2027 * -3,080x
Enterprise Value 1.24B 1.07B 1B 914M 1.72B 118B 1.75B 11.77B 4.6B 59.28B 4.65B 4.55B 197B EV / Sales 2026 *
2.79x
EV / Sales 2027 * 2.46x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day+3.22%
1 week-6.33%
Current month-1.53%
1 month-0.77%
3 months+19.57%
6 months-31.98%
Current year-32.10%
1 week 3.63
Extreme 3.63
4.08
1 month 3.63
Extreme 3.63
4.24
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap.
07/08/26 Sell

Director

-39,051 0.0122%
17/07/26 Sell

General Counsel

-24,109 0.0078%
17/07/26 Sell

Director

-52,485 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
+3.22%-6.33%+4.05%-26.94% 1.24B
-1.90%+2.85%+61.37%+102.88% 70.07B
-3.21%-4.32%+31.19%+59.75% 52.87B
-2.05%-5.61%-3.14%+454.89% 27.02B
-1.27%-1.57%+46.46%+6.09% 23.61B
+1.05%-0.62%-17.40%-13.36% 23.38B
+3.81%+20.97%+263.48%+552.47% 19.43B
+0.10%+1.40%+38.98%-20.04% 18.75B
-0.95%-3.52%+20.04%+613.01% 15.85B
+1.24%-5.23%+33.19%+138.21% 12.7B
Average +0.00%+1.12%+47.82%+186.70% 26.49B
Weighted average by Cap. -1.07%+0.52%+49.63%+167.18%

Financials

2026 *2027 *
Net sales 443M 383M 360M 327M 615M 42.4B 626M 4.22B 1.65B 21.23B 1.66B 1.63B 70.56B 504M 435M 409M 372M 699M 48.2B 711M 4.79B 1.87B 24.14B 1.89B 1.85B 80.21B
Net income -57.18M -49.38M -46.41M -42.2M -79.35M -5.47B -80.65M -544M -213M -2.74B -215M -210M -9.1B 27.12K 23.42K 22.01K 20.02K 37.63K 2.59M 38.26K 258K 101K 1.3M 102K 99.61K 4.32M
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
14/08/26 US$3.850 +3.22% 2,855,400
13/08/26 US$3.730 -3.12% 5,239,892
12/08/26 US$3.850 +0.26% 3,055,998
11/08/26 US$3.840 -2.29% 4,497,586
10/08/26 US$3.930 -4.38% 4,157,384
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.850USD
Average target price
7.969USD
Spread / Average Target
+106.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock